PROCEPT BioRobotics Corp — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
PROCEPT reported Q2 2026 revenue of $94.5M (vs. $79.2M YoY, +19%), with U.S. procedures at 13,100 (+21% YoY) and 65 HYDROS systems placed at ~$495K per unit. Gross margin improved to 66% (from 65% YoY), but operating expenses rose to $89.8M (from $73.9M), resulting in net loss of $26.9M (vs. $19.6M loss YoY). Company reiterated full-year 2026 revenue guidance of $390M–$410M (+27–33% YoY) and now guides adjusted EBITDA loss of $30M–$35M (previously $35M–$30M range, suggesting slight improvement). Cash position: $231M as of June 30, 2026.
Why this rating
Solid operational execution (revenue +19%, procedures +21%) and margin expansion offset by widening GAAP losses and flat guidance reiteration. Modest cash burn and positive procedure momentum are routine for a $3.2B growth-stage medtech company; not trajectory-altering.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.